Neurocrine Biosciences

Youtube Subscribe

Open: 120.89 Close: 119.92 Change: -0.97

Can you guess what an AI found about Neurocrine Biosciences.

The game is changing. There is a new strategy to evaluate Neurocrine Biosciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, Inc, company, stock, analysis, new, …

Concept Map

Semantic Network

Stock Summary

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Its products include INGREZZA and DYSVAL, for the treatment of tardive dys.

Today's Summary

Neurocrine Biosciences (NBIX) will report earnings of for Q4 2023 on February 05, 2024. State Street Corp lifted its position in shares by 4.1%.

Today's News

Neurocrine biosciences, inc. (nbix) stock price, quote, news & analysis. Join now Search for Symbols, analysts, keywords and symbols. Neurocrine Biosciences, Inc. will present a new post hoc analysis of Phase 2 data of the investigational drug crinecece. Neurocrine Biosciences Inc. per Employee $1.487M P/E Ratio 64.16 EPS $/A Dividend N/A Ex-Dividend Date N/a Short Interest 2.11M 11/30/23 % of Float Shorted 2.21%. Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders. Chief Medical Officer Eiry Roberts, the Chief Medical. Officer of Neurocrines Inc, is a significant insider sell. Neurocrine Biosciences (NBIX) will report earnings of for Q4 2023 on February 05, 2024. Illumina plans to sell its Grail unit, Roku stock receives another downgrade to Sell. Uber joins the S&P 500. Comerica Bank purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - defense world.com. State Street Corp lifted its position in shares by 4.1% in second quarter. Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company. The company is looking for a Psychiatry Account Specialist.

Stock Profile

"Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."

Keywords

How much time have you spent trying to decide whether investing in Neurocrine Biosciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, Inc, company, stock, analysis, new, and the most common words in the summary are: neurocrine, bioscience, inc, job, stock, share, news, . One of the sentences in the summary was: State Street Corp lifted its position in shares by 4.1%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #neurocrine #bioscience #inc #job #stock #share #news.

Read more →

Youtube Subscribe

---